Diabetic cardiovascular disease

1. International Diabetes Federation. IDF diabetes atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.[Full Text]

2. International Diabetes Federation. Diabetes and cardiovascular disease. Brussels, Belgium: International Diabetes Federation; 2016.[Full Text]

3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016 Apr 6;387(10027):1513-30.[Abstract][Full Text]

4. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 Heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-913.[Abstract][Full Text]

5. GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023 Jul 15;402(10397):203-34.[Abstract][Full Text]

6. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-140.[Full Text]

7. Feleke BE, Sacre J, Tomic D, et al. Hospital admissions among people with diabetes: a systematic review. Diabet Med. 2024 Jan;41(1):e15236.[Abstract]

8. Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1·9 million people. Lancet Diabetes Endocrinol. 2015 Feb;3(2):105-13.[Abstract][Full Text]

9. Cosentino F, Verma S, Ambery P, et al. Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table. Eur Heart J. 2023 Oct 14;44(39):4141-56.[Abstract][Full Text]

10. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015 Oct 10;6(13):1246-58.[Abstract][Full Text]

11. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017 Apr 13;376(15):1407-18.[Abstract][Full Text]

12. Gyldenkerne C, Kahlert J, Olesen KKW, et al. Twenty-year temporal trends in risk of ischemic stroke in incident type 2 diabetes: a Danish population-based cohort study. Diabetes Care. 2022 Sep 1;45(9):2144-51.[Abstract][Full Text]

13. Gyldenkerne C, Knudsen JS, Olesen KKW, et al. Nationwide trends in cardiac risk and mortality in patients with incident type 2 diabetes: a Danish cohort study. Diabetes Care. 2021 Aug 11 [Epub ahead of print].[Abstract]

14. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014 Aug 11;130(13):1110-30.[Full Text]

15. Harjutsalo V, Pongrac Barlovic D, Groop PH. Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study. Lancet Diabetes Endocrinol. 2021 Sep;9(9):575-85.[Abstract]

16. Harjutsalo V, Barlovic DP, Gordin D, et al. Presence and determinants of cardiovascular disease and mortality in individuals with type 1 diabetes of long duration: the FinnDiane 50 years of diabetes study. Diabetes Care. 2021 Aug;44(8):1885-93.[Abstract][Full Text]

17. Standl E, Khunti K, Hansen TB, et al. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019 Dec;26(2 Suppl):7-14.[Abstract][Full Text]

18. Fleg JL, Forman DE, Berra K, et al; American Heart Association. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013 Nov 26;128(22):2422-46.[Full Text]

19. Klein L, Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am J Med. 2004 Mar 8;116(suppl 5A):47-63S.[Abstract]

20. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004 Jan;27(1):201-7.[Abstract][Full Text]

21. Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun;165(6):918-25.[Abstract]

22. Sacre JW, Magliano DJ, Shaw JE. Incidence of hospitalization for heart failure relative to major atherosclerotic events in type 2 diabetes: a meta-analysis of cardiovascular outcomes trials. Diabetes Care. 2020 Oct;43(10):2614-23.[Abstract][Full Text]

23. Pandey A, Khan MS, Patel KV, et al. Predicting and preventing heart failure in type 2 diabetes. Lancet Diabetes Endocrinol. 2023 Aug;11(8):607-24.[Abstract]

24. Wamil M, Coleman RL, Adler AI, et al. Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89. Diabetes Care. 2021 Aug;44(8):1877-84.[Abstract][Full Text]

25. Chen R, Ovbiagele B, Feng W. Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci. 2016 Apr;351(4):380-6.[Abstract][Full Text]

26. Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract. 2006 Jan;60(1):48-56.[Abstract]

27. Zhang L, Li X, Wolfe CDA, et al. Diabetes as an independent risk factor for stroke recurrence in ischemic stroke patients: an updated meta-analysis. Neuroepidemiology. 2021;55(6):427-35.[Abstract][Full Text]

28. Writing Committee Members, Gornik HL, Aronow HD, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 18;83(24):2497-604.[Abstract][Full Text]

29. American Diabetes Association. Standards of care in diabetes - 2024​. Diabetes Care 2024 Jan 1;47(suppl 1):S1-321. [Full Text]

30. Barnes JA, Eid MA, Creager MA, et al. Epidemiology and risk of amputation in patients with diabetes and peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020 Aug;40(8):1808-17.[Abstract][Full Text]

31. Golledge J, Clancy P, Jamrozik K, et al. Obesity, adipokines, and abdominal aortic aneurysm. Health in Men study. Circulation. 2007 Nov 13;116(20):2275-9.[Abstract][Full Text]

32. Dattani N, Sayers RD, Bown MJ. Diabetes mellitus and abdominal aortic aneurysms: a review of the mechanisms underlying the negative relationship. Diab Vasc Dis Res. 2018 Sep;15(5):367-74.[Abstract][Full Text]

33. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J. 2008 Mar;29(5):665-72.[Abstract]

34. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022 Mar 20;23(6):3346.[Abstract][Full Text]

35. Shanik MH, Xu Y, Skrha J, et al. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008 Feb;31 Suppl 2:S262-8.[Abstract][Full Text]

36. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019 Mar 4;21(4):21.[Abstract]

37. Yaribeygi H, Atkin SL, Sahebkar A. A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress. J Cell Physiol. 2019 Feb;234(2):1300-12.[Abstract]

38. Kaplan M, Aviram M, Hayek T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacol Ther. 2012 Nov;136(2):175-85.[Abstract]

39. Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci. 2016 Dec 3;23(1):87.[Abstract][Full Text]

40. Yahagi K, Kolodgie FD, Lutter C, et al. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017 Feb;37(2):191-204.[Abstract][Full Text]

41. Yuan T, Yang T, Chen H, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019 Jan;20:247-60.[Abstract][Full Text]

42. Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol. 2002 Sep 4;40(5):946-53.[Abstract]

43. Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. Circulation. 1996 Oct 15;94(8):1818-25.[Abstract][Full Text]

44. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-35.[Abstract][Full Text]

45. Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023 Dec 12;148(24):1982-2004.[Abstract][Full Text]

46. Hamjane N, Mechita MB, Nourouti NG, et al. Gut microbiota dysbiosis -associated obesity and its involvement in cardiovascular diseases and type 2 diabetes. A systematic review. Microvasc Res. 2024 Jan;151:104601.[Abstract]

47. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022 Mar;145(9):e722-59.[Abstract][Full Text]

48. Campagna D, Alamo A, Di Pino A, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2019 Oct 24;11:85.[Abstract][Full Text]

49. Pan A, Wang Y, Talaei M, et al. Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Dec;3(12):958-67.[Abstract][Full Text]

50. U.S. Department of Health and Human Services. The health consequences of smoking-50 years of progress​: a report of the surgeon general. 2014 [internet publication].[Full Text]

51. Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension. 2021 Nov;78(5):1197-205.[Abstract][Full Text]

52. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018 May;34(5):575-84.[Abstract][Full Text]

53. Seng LL, Hai Kiat TP, Bee YM, et al. Real-world systolic and diastolic blood pressure levels and cardiovascular mortality in patients with type 2 diabetes-results from a large registry cohort in Asia. J Am Heart Assoc. 2023 Dec 5;12(23):e030772.[Abstract][Full Text]

54. Ahmed A, Amin H, Drenos F, et al. Genetic evidence strongly supports managing weight and blood pressure in addition to glycemic control in preventing vascular complications in people with type 2 diabetes. Diabetes Care. 2023 Oct 1;46(10):1783-91.[Abstract][Full Text]

55. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021 May 1;397(10285):1625-36.[Abstract][Full Text]

56. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.[Abstract][Full Text]

57. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.[Abstract][Full Text]

58. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998 Sep 12;317(7160):703-13.[Abstract][Full Text]

59. Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021 Sep 30;385(14):1268-79.[Abstract][Full Text]

60. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.[Abstract][Full Text]

61. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022 Oct;28(10):923-1049.[Abstract][Full Text]

62. Kane JP, Pullinger CR, Goldfine ID, et al. Dyslipidemia and diabetes mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus. Curr Opin Pharmacol. 2021 Dec;61:21-7.[Abstract][Full Text]

63. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013 Mar;73(4):327-39.[Abstract]

64. Bancks MP, Ning H, Allen NB, et al. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019 Jan 7;42(3):457-65.[Abstract]

65. Li F, Zhang L, Shen Y, et al. Higher glucose fluctuation is associated with a higher risk of cardiovascular disease: insights from pooled results among patients with diabetes. J Diabetes. 2023 May;15(5):368-81.[Abstract][Full Text]

66. Wang T, Zhang X, Liu J. Long-term glycemic variability and risk of cardiovascular events in type 2 diabetes: a meta-analysis. Horm Metab Res. 2022 Feb;54(2):84-93.[Abstract]

67. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009 Jan;32(1):187-92.[Abstract][Full Text]

68. Wahid A, Manek N, Nichols M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc. 2016 Sep 14;5(9):e002495.[Abstract][Full Text]

69. Vasankari V, Husu P, Vähä-Ypyä H, et al. Association of objectively measured sedentary behaviour and physical activity with cardiovascular disease risk. Eur J Prev Cardiol. 2017 Aug;24(12):1311-8.[Abstract][Full Text]

70. Bazargan-Hejazi S, Arroyo JS, Hsia S, et al. A racial comparison of differences between self-reported and objectively measured physical activity among US adults with diabetes. Ethn Dis. 2017 Fall;27(4):403-10.[Abstract][Full Text]

71. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016 Nov;39(11):2065-79.[Full Text]

72. Rietz M, Lehr A, Mino E, et al. Physical activity and risk of major diabetes-related complications in individuals with diabetes: a systematic review and meta-analysis of observational studies. Diabetes Care. 2022 Dec 1;45(12):3101-11.[Abstract][Full Text]

73. Cassidy S, Thoma C, Hallsworth K, et al. High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2016 Jan;59(1):56-66.[Abstract][Full Text]

74. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016 May 27;118(11):1723-35.[Abstract][Full Text]

75. Van der Schueren B, Ellis D, Faradji RN, et al. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021 Nov;9(11):776-85.[Abstract]

76. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019 Sep 10;140(11):e596-646.[Abstract][Full Text]

77. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001 Jul 25;286(4):421-6.[Abstract][Full Text]

78. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003 Dec 2;139(11):901-6.[Abstract]

79. Fangel MV, Nielsen PB, Kristensen JK, et al. Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: a Danish cohort study. Am J Med. 2020 Jun;133(6):e269-79.[Abstract]

80. Schulze MB, Rimm EB, Li T, et al. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004 Apr;27(4):889-94.[Abstract][Full Text]

81. Jeong H, Baek SY, Kim SW, et al. C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey. BMJ Open. 2019 Aug 30;9(8):e029861.[Abstract][Full Text]

82. Hayfron-Benjamin CF, Maitland-van der Zee AH, van den Born BJ, et al. Association between C reactive protein and microvascular and macrovascular dysfunction in sub-Saharan Africans with and without diabetes: the RODAM study. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001235.[Abstract][Full Text]

83. Huxley RR, Peters SA, Mishra GD, et al. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Mar;3(3):198-206.[Abstract]

84. Wang H, Ba Y, Cai RC, et al. Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. BMJ Open. 2019 Jul 17;9(7):e024935.[Abstract][Full Text]

85. Xu G, You D, Wong L, et al. Risk of all-cause and CHD mortality in women versus men with type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019 Apr;180(4):243-55.[Abstract][Full Text]

86. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014 Aug;57(8):1542-51.[Abstract][Full Text]

87. Ohkuma T, Komorita Y, Peters SAE, et al. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019 Sep;62(9):1550-60.[Abstract][Full Text]

88. Yaow CYL, Chong B, Chin YH, et al. Higher risk of adverse cardiovascular outcomes in females with type 2 diabetes Mellitus: an umbrella review of systematic reviews. Eur J Prev Cardiol. 2023 Sep 6;30(12):1227-35.[Abstract]

89. Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021 Jun 19;397(10292):2385-438.[Abstract]

90. Yoshida Y, Chen Z, Baudier RL, et al. Early menopause and cardiovascular disease risk in women with or without type 2 diabetes: a pooled analysis of 9,374 postmenopausal women. Diabetes Care. 2021 Nov;44(11):2564-72.[Abstract][Full Text]

91. Peters SA, Huxley RR, Sattar N, et al. Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. Curr Cardiovasc Risk Rep. 2015;9(7):36.[Abstract][Full Text]

92. Connelly PJ, Marie Freel E, Perry C, et al. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension. 2019 Dec;74(6):1266-74.[Abstract][Full Text]

93. Yoshida Y, Chen Z, Baudier RL, et al. Menopausal hormone therapy and risk of cardiovascular events in women with prediabetes or type 2 diabetes: a pooled analysis of 2917 postmenopausal women. Atherosclerosis. 2022 Mar;344:13-19.[Abstract][Full Text]

94. Mehta LS, Velarde GP, Lewey J, et al. Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association. Circulation. 2023 May 9;147(19):1471-87.[Abstract][Full Text]

95. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019 Jun;62(6):905-14.[Abstract][Full Text]

96. Xie W, Wang Y, Xiao S, et al. Association of gestational diabetes mellitus with overall and type specific cardiovascular and cerebrovascular diseases: systematic review and meta-analysis. BMJ. 2022 Sep 21;378:e070244.[Abstract][Full Text]

97. Polcwiartek C, O'Gallagher K, Friedman DJ, et al. Severe mental illness: cardiovascular risk assessment and management. Eur Heart J. 2024 Mar 27;45(12):987-97.[Abstract][Full Text]

98. Osborn DP, Hardoon S, Omar RZ, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry. 2015 Feb;72(2):143-51.[Abstract][Full Text]

99. Wang X, Ma H, Li X, et al. Joint association of loneliness and traditional risk factor control and incident cardiovascular disease in diabetes patients. Eur Heart J. 2023 Jul 21;44(28):2583-91.[Abstract][Full Text]

100. Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022 Jun;42(6):e168-85.[Abstract][Full Text]

101. Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023 Aug;17(4):773-91.[Abstract][Full Text]

102. Kim KS, Hong S, Han K, et al. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024 Feb 13;384:e076388.[Abstract][Full Text]

103. Kwon S, Lee SR, Choi EK, et al. Association between atrial fibrillation and diabetes-related complications: a nationwide cohort study. Diabetes Care. 2023 Dec 1;46(12):2240-8.[Abstract][Full Text]

104. Karayiannides S, Lundman P, Friberg L, et al. High overall cardiovascular risk and mortality in patients with atrial fibrillation and diabetes: a nationwide report. Diab Vasc Dis Res. 2018 Jan;15(1):31-8.[Abstract][Full Text]

105. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 Sep 1;104(9):3939-85.[Abstract][Full Text]

106. Gregg EW, Chen H, Bancks MP, et al. Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study. Diabetologia. 2024 Mar;67(3):459-69.[Abstract][Full Text]

107. Choi YJ, Han KD, Choi EK, et al. Alcohol abstinence and the risk of atrial fibrillation in patients with newly diagnosed type 2 diabetes mellitus: a nationwide population-based study. Diabetes Care. 2021 Jun;44(6):1393-401.[Abstract][Full Text]

108. Bowman L, Mafham M, Wallendszus K, et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Aug 26;379(16):1529-39.[Abstract][Full Text]

109. Patel NJ, Baliga RR. Role of aspirin for primary prevention in persons with diabetes mellitus and in the elderly. Curr Cardiol Rep. 2020 May 29;22(7):48.[Abstract]

110. US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: preventive medication. Apr 2022 [internet publication].[Full Text]

111. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21;38(32):2459-72.[Abstract][Full Text]

112. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019 Jun 18;139(25):e1082-143.[Abstract][Full Text]

113. Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020 May 12;141(19):e779-806.[Abstract][Full Text]

114. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.[Abstract][Full Text]

115. Bosch J, Gerstein HC, Dagenais GR, et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 Jul 26;367(4):309-18.[Abstract][Full Text]

116. Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022 Apr 1;45(4):909-18.[Abstract]

117. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2018 Jan 23;137(4):323-34.[Abstract][Full Text]

118. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347-57.[Abstract][Full Text]

119. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019 May 28;139(22):2528-36.[Abstract][Full Text]

120. Rahman H, Khan SU, Lone AN, et al. Sodium-glucose cotransporter-2 inhibitors and primary prevention of atherosclerotic cardiovascular disease: a meta-analysis of randomized trials and systematic review. J Am Heart Assoc. 2023 Aug 15;12(16):e030578.[Abstract][Full Text]

121. Yahyavi SK, Snorgaard O, Knop FK, et al. Prediabetes defined by first measured HbA1c predicts higher cardiovascular risk compared with HbA1c in the diabetes range: a cohort study of nationwide registries. Diabetes Care. 2021 Dec;44(12):2767-74.[Abstract]

122. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008 Jan 12;371(9607):117-25.[Abstract]

123. Mechanick JI, Farkouh ME, Newman JD, et al. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps: JACC state-of-the-art review. J Am Coll Cardiol. 2020 Feb 11;75(5):539-55.[Abstract][Full Text]

124. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024 Mar 16;403(10431):1027-50.[Abstract][Full Text]

125. Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Evidence-based European recommendations for the dietary management of diabetes. Diabetologia. 2023 Jun;66(6):965-85.[Abstract][Full Text]

126. Zhao B, Zeng L, Zhao J, et al. Association of magnesium intake with type 2 diabetes and total stroke: an updated systematic review and meta-analysis. BMJ Open. 2020 Mar 19;10(3):e032240.[Abstract][Full Text]

127. Chen Z, Khandpur N, Desjardins C, et al. Ultra-processed food consumption and risk of type 2 diabetes: three large prospective U.S. cohort studies. Diabetes Care. 2023 Jul 1;46(7):1335-44.[Abstract][Full Text]

128. Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2022 Jan;10(1):24-34.[Abstract]

129. Holman RR, Haffner SM, McMurray JJ, et al; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22;362(16):1463-76.[Abstract][Full Text]

130. Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021 Nov 13;398(10313):1803-10.[Abstract][Full Text]

131. McMurray JJ, Holman RR, Haffner SM, et al; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22;362(16):1477-90.[Abstract][Full Text]

132. Creager MA. Medical management of peripheral arterial disease. Cardiol Rev. 2001 Jul-Aug;9(4):238-45.[Abstract]

133. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: an underappreciated complication of diabetes - a consensus report of the American Diabetes Association. Diabetes Care. 2022 Jul 7;45(7):1670-90.[Abstract][Full Text]

134. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013 Aug 20;128(8):873-934.[Abstract][Full Text]

135. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021 Nov 30;144(22):e368-454.[Abstract][Full Text]

136. Grundy SM, Howard B, Smith S Jr, et al. Prevention conference VI: diabetes and cardiovascular disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002 May 7;105(18):2231-9.[Full Text]

137. Lee DP, Fearon WF, Froelicher VF. Clinical utility of the exercise ECG in patients with diabetes and chest pain. Chest. 2001 May;119(5):1576-81.[Abstract]

138. Patel AR, Salerno M, Kwong RY, et al. Stress cardiac magnetic resonance myocardial perfusion imaging: JACC review topic of the week. J Am Coll Cardiol. 2021 Oct 19;78(16):1655-68.[Abstract]

139. Bax JJ, Young LH, Frye RL, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007 Oct;30(10):2729-36.[Abstract][Full Text]

140. Berman DS, Hachamovitch R, Shaw LJ, et al. Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: noninvasive risk stratification and a conceptual framework for the selection of noninvasive imaging tests in patients with known or suspected coronary artery disease. J Nucl Med. 2006 Jul;47(7):1107-18.[Abstract][Full Text]

141. Muhlestein JB, Lappé DL, Lima JA, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014 Dec 3;312(21):2234-43.[Abstract]

142. Henry TD, Tomey MI, Tamis-Holland JE, et al. Invasive management of acute myocardial infarction complicated by cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2021 Apr 13;143(15):e815-29.[Abstract][Full Text]

143. DeVon HA, Zerwic JJ. Symptoms of acute coronary syndromes: are there gender differences? A review of the literature. Heart Lung. 2002 Jul-Aug;31(4):235-45.[Abstract]

144. Yew KS, Cheng EM. Diagnosis of acute stroke. Am Fam Physician. 2015 Apr 15;91(8):528-36.[Abstract][Full Text]

145. Grönberg A, Henriksson I, Stenman M, et al. Incidence of aphasia in ischemic stroke. Neuroepidemiology. 2022;56(3):174-82.[Abstract][Full Text]

146. Rowe F, VIS group UK. Prevalence of ocular motor cranial nerve palsy and associations following stroke. Eye (Lond). 2011 Jul;25(7):881-7.[Abstract][Full Text]

147. Szaflarski JP, Rackley AY, Kleindorfer DO, et al. Incidence of seizures in the acute phase of stroke: a population-based study. Epilepsia. 2008 Jun;49(6):974-81.[Abstract][Full Text]

148. Harriott AM, Karakaya F, Ayata C. Headache after ischemic stroke: a systematic review and meta-analysis. Neurology. 2020 Jan 7;94(1):e75-86.[Abstract][Full Text]

149. Morley RL, Sharma A, Horsch AD, et al. Peripheral artery disease. BMJ. 2018 Feb 1;360:j5842.

150. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022 May 3;145(18):e895-1032.[Abstract][Full Text]

151. Abdulhannan P, Russell DA, Homer-Vanniasinkam S. Peripheral arterial disease: a literature review. Br Med Bull. 2012;104:21-39.[Abstract][Full Text]

152. Pickett CA, Jackson JL, Hemann BA, et al. Carotid bruits and cerebrovascular disease risk: a meta-analysis. Stroke. 2010 Oct;41(10):2295-302.[Abstract][Full Text]

153. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. J Am Coll Cardiol. 2011 Feb 22;57(8):e16-94.[Abstract][Full Text]

154. Emberson J, Bennett D, Link E, et al; Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011 Feb 5;377(9764):469-76.[Abstract][Full Text]

155. US Preventive Services Task Force. Prediabetes and type 2 diabetes: screening. August 2021 [internet publication].[Full Text]

156. Di Angelantonio E, Gao P, Khan H, et al; Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014 Mar 26;311(12):1225-33.[Abstract][Full Text]

157. Lièvre MM, Moulin P, Thivolet C, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials. 2011 Jan 26;12:23.[Abstract][Full Text]

158. Rados DV, Pinto LC, Leitão CB, et al. Screening for coronary artery disease in patients with type 2 diabetes: a meta-analysis and trial sequential analysis. BMJ Open. 2017 May 9;7(5):e015089.[Abstract][Full Text]

159. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023 Oct 12;44(38):3720-826.[Full Text]

160. Kelsey MD, Nelson AJ, Green JB, et al. Guidelines for cardiovascular risk reduction in patients with type 2 diabetes: JACC guideline comparison. J Am Coll Cardiol. 2022 May 10;79(18):1849-57.[Abstract][Full Text]

161. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018 Aug 16;379(7):633-44.[Abstract][Full Text]

162. Arnold SV, de Lemos JA, Rosenson RS, et al; GOULD Investigators. Use of guideline-recommended risk-reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation. 2019 Aug 13;140(7):618-20.[Abstract][Full Text]

163. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 Apr 18;42(5):731-54.[Abstract][Full Text]

164. Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010 Sep 27;170(17):1566-75.[Abstract][Full Text]

165. Elhayany A, Lustman A, Abel R, et al. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Diabetes Obes Metab. 2010 Mar;12(3):204-9.[Abstract]

166. Wormgoor SG, Dalleck LC, Zinn C, et al. Effects of high-intensity interval training on people living with type 2 diabetes: a narrative review. Can J Diabetes. 2017 Oct;41(5):536-47.[Abstract]

167. O'Connor EA, Evans CV, Rushkin MC, et al. Behavioral counseling to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2020 Nov 24;324(20):2076-94.[Abstract][Full Text]

168. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. Endocr Pract. 2023 May;29(5):305-40.[Abstract][Full Text]

169. Karmali R, Sipko J, Majid M, et al. Hyperlipidemia and cardiovascular disease in people with type 1 diabetes: review of current guidelines and evidence. Curr Cardiol Rep. 2023 May;25(5):435-42.[Abstract]

170. Wheeler ML, Dunbar SA, Jaacks LM, et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. Diabetes Care. 2012 Feb;35(2):434-45.[Abstract][Full Text]

171. Esposito K, Maiorino MI, Ciotola M, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009 Sep 1;151(5):306-14.[Abstract]

172. Azadbakht L, Fard NR, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011 Jan;34(1):55-7.[Abstract][Full Text]

173. Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006 Aug;29(8):1777-83.[Abstract][Full Text]

174. Wang T, Kroeger CM, Cassidy S, et al. Vegetarian dietary patterns and cardiometabolic risk in people with or at high risk of cardiovascular disease: a systematic review and meta-analysis. JAMA Netw Open. 2023 Jul 3;6(7):e2325658.[Abstract][Full Text]

175. Shi W, Huang X, Schooling CM, et al. Red meat consumption, cardiovascular diseases, and diabetes: a systematic review and meta-analysis. Eur Heart J. 2023 Jul 21;44(28):2626-35.[Abstract][Full Text]

176. Neuenschwander M, Stadelmaier J, Eble J, et al. Substitution of animal-based with plant-based foods on cardiometabolic health and all-cause mortality: a systematic review and meta-analysis of prospective studies. BMC Med. 2023 Nov 16;21(1):404.[Abstract][Full Text]

177. Hu Y, Liu G, Yu E, et al. Low-carbohydrate diet scores and mortality among adults with incident type 2 diabetes. Diabetes Care. 2023 Apr 1;46(4):874-84.[Abstract][Full Text]

178. World Health Organization. Carbohydrate intake for adults and children: WHO guideline. Jul 2023 [internet publication].​[Full Text]

179. Jenkins DJA, Willett WC, Yusuf S, et al. Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants. Lancet Diabetes Endocrinol. 2024 Feb;12(2):107-18.[Abstract]

180. Schwab U, Reynolds AN, Sallinen T, et al. Dietary fat intakes and cardiovascular disease risk in adults with type 2 diabetes: a systematic review and meta-analysis. Eur J Nutr. 2021 Sep;60(6):3355-63.[Abstract]

181. World Health Organization. Saturated fatty acid and trans-fatty acid intake for adults and children: WHO guideline. Jul 2023 [internet publication].​[Full Text]

182. Churuangsuk C, Hall J, Reynolds A, et al. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022 Jan;65(1):14-36.[Abstract][Full Text]

183. Tagde P, Tagde S, Bhattacharya T, et al. Multifaceted effects of intermittent fasting on the treatment and prevention of diabetes, cancer, obesity or other chronic diseases. Curr Diabetes Rev. 2022;18(9):e131221198789.[Abstract]

184. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-51.[Abstract]

185. Dambha-Miller H, Hounkpatin HO, Stuart B, et al. Type 2 diabetes remission trajectories and variation in risk of diabetes complications: a population-based cohort study. PLoS One. 2023;18(8):e0290791.[Abstract][Full Text]

186. Batty GD, Shipley MJ, Marmot M, et al. Physical activity and cause-specific mortality in men with type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study. Diabet Med. 2002 Jul;19(7):580-8.[Abstract]

187. Tikkanen-Dolenc H, Wadén J, Forsblom C, et al. Physical activity reduces risk of premature mortality in patients with type 1 diabetes with and without kidney disease. Diabetes Care. 2017 Dec;40(12):1727-32.[Abstract]

188. Kemps H, Kränkel N, Dörr M, et al. Exercise training for patients with type 2 diabetes and cardiovascular disease: what to pursue and how to do it - position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2019 May;26(7):709-27.[Abstract][Full Text]

189. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014 Jul;312(2):155-61.[Abstract][Full Text]

190. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022 Jul 21;387(3):205-16.[Abstract][Full Text]

191. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023 Aug 19;402(10402):613-26.[Abstract]

192. Małecki MT, Batterham RL, Sattar N, et al. Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1-4. Diabetes Care. 2023 Dec 1;46(12):2292-9.[Abstract][Full Text]

193. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021 Jan 13;372:m4573.[Abstract][Full Text]

194. Courcoulas AP, Patti ME, Hu B, et al. Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA. 2024 Feb 27;331(8):654-64.[Abstract][Full Text]

195. Hussain S, Khan MS, Jamali MC, et al. Impact of bariatric surgery in reducing macrovascular complications in severely obese T2DM patients. Obes Surg. 2021 May;31(5):1929-36.[Abstract]

196. Cohen R, Sforza NS, Clemente RG. Impact of metabolic surgery on type 2 diabetes mellitus, cardiovascular risk factors, and mortality: a review. Curr Hypertens Rev. 2021;17(2):159-69.[Abstract]

197. Cui B, Wang G, Li P, et al. Disease-specific mortality and major adverse cardiovascular events after bariatric surgery: a meta-analysis of age, sex, and BMI-matched cohort studies. Int J Surg. 2023 Mar 1;109(3):389-400.[Abstract][Full Text]

198. Obeso-Fernández J, Millan-Alanis JM, Sáenz-Flores M, et al. Benefits of metabolic surgery on macrovascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis. Surg Obes Relat Dis. 2024 Feb;20(2):202-12.[Abstract]

199. Cavero-Redondo I, Peleteiro B, Álvarez-Bueno C, et al. Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis. BMJ Open. 2017 Jul 31;7(7):e015949.[Abstract][Full Text]

200. Hasebe M, Yoshiji S, Keidai Y, et al. Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovasc Diabetol. 2023 Mar 19;22(1):62.[Abstract][Full Text]

201. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39.[Abstract][Full Text]

202. Reaven PD, Emanuele NV, Wiitala WL, et al; VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019 Jun 6;380(23):2215-24.[Abstract]

203. ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016 Jan 28;39(5):701-8.[Abstract][Full Text]

204. Zoungas S, Chalmers J, Ninomiya T, et al; ADVANCE Collaborative Group. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2011 Dec 21;55(3):636-43.[Abstract][Full Text]

205. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC Study 30-year follow-up. Diabetes Care. 2016 Feb 9;39(5):686-93.[Abstract][Full Text]

206. Kunutsor SK, Balasubramanian VG, Zaccardi F, et al. Glycaemic control and macrovascular and microvascular outcomes: a systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes. Diabetes Obes Metab. 2024 Jun;26(6):2069-81.[Abstract][Full Text]

207. Hayward RA, Reaven PD, Wiitala WL, et al; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jun 4;372(23):2197-206.[Abstract][Full Text]

208. Gerstein HC, Miller ME, Ismail-Beigi F, et al; ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014 Nov 29;384(9958):1936-41.[Abstract][Full Text]

209. Holman R, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.[Abstract][Full Text]

210. Gerstein HC, Miller ME, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 6;358(24):2545-59.[Abstract][Full Text]

211. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.[Abstract][Full Text]

212. Qaseem A, Obley AJ, Shamliyan T, et al. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians. Ann Intern Med. 2024 May;177(5):658-66.[Abstract][Full Text]

213. Diallo A, Villard O, Carlos-Bolumbu M, et al. Effects of hypoglycaemic agents on reducing surrogate metabolic parameters for the prevention of cardiovascular events and death in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2024 Feb;26(2):495-502.[Abstract]

214. Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023 Apr 6;381:e074068.[Abstract][Full Text]

215. Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-45.[Abstract][Full Text]

216. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-62.[Abstract]

217. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018 Nov 10;393(10166):31-9.[Abstract]

218. Zerovnik S, Kos M, Locatelli I. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study. BMJ Open. 2021 Sep 13;11(9):e051549.[Abstract][Full Text]

219. Kunutsor SK, Zaccardi F, Balasubramanian VG, et al. Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents. Diabetes Obes Metab. 2024 May;26(5):1837-49.[Abstract][Full Text]

220. Mellbin LG, Bhatt DL, David JP, et al. Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. Eur Heart J. 2024 Apr 14;45(15):1371-4.[Full Text]

221. Huang X, Dannya E, Liu X, et al. Effect of sodium-glucose cotransporter-2 inhibitors on myocardial infarction incidence: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Diabetes Obes Metab. 2024 Mar;26(3):1040-9.[Abstract]

222. Yoshihara F, Imazu M, Sakuma I, et al. DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial. EClinicalMedicine. 2023 Dec;66:102334.[Abstract][Full Text]

223. Sohn M, Frias JP, Lim S. Cardiovascular efficacy and safety of antidiabetic agents: a network meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2023 Dec;25(12):3560-77.[Abstract]

224. Xie Y, Bowe B, Xian H, et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 2023 Sep;11(9):644-56.[Abstract]

225. Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650.[Abstract][Full Text]

226. Diallo A, Carlos-Bolumbu M, Galtier F. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2023 Dec;60(12):1651-1662.[Abstract][Full Text]

227. Eraikhuemen N, Leung S, Warren SB, et al. Effects of the sodium-glucose cotransporter inhibitors on cardiovascular death and all-cause mortality: a systematic review and meta-analysis of randomized placebo-controlled clinical trials. Am J Cardiovasc Drugs. 2023 Mar;23(2):113-26.[Abstract]

228. Hinton W, Ansari AS, Whyte MB, et al. Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? a systematic review and meta-analysis of observational studies. Diabetes Obes Metab. 2023 Feb;25(2):501-15.[Abstract]

229. Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022 May 26;386(21):2024-34.[Abstract]

230. Jhalani NB. Clinical Considerations for use of SGLT2 inhibitor therapy in patients with heart failure and reduced ejection fraction: a review. Adv Ther. 2022 Aug;39(8):3472-87.[Abstract][Full Text]

231. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14;385(16):1451-61.[Abstract][Full Text]

232. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022 Sep 22;387(12):1089-98.[Abstract][Full Text]

233. Usman MS, Siddiqi TJ, Anker SD, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. J Am Coll Cardiol. 2023 Jun 27;81(25):2377-87.[Abstract][Full Text]

234. Chen J, Jiang C, Guo M, et al. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovasc Diabetol. 2024 Jan 3;23(1):2.[Abstract][Full Text]

235. De Marzo V, Savarese G, Porto I, et al. Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction. J Cardiovasc Med (Hagerstown). 2023 Aug 1;24(8):537-43.[Abstract]

236. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 Sep 3;400(10354):757-67.[Abstract]

237. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.[Abstract][Full Text]

238. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-306.[Abstract][Full Text]

239. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019 Aug 27;140(9):739-50.[Abstract][Full Text]

240. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018 Oct 23;138(17):1904-7.[Abstract][Full Text]

241. Ali AE, Mazroua MS, ElSaban M, et al. Effect of dapagliflozin in patients with heart failure: a systematic review and meta-analysis. Glob Heart. 2023 Aug 22;18(1):45.[Abstract][Full Text]

242. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.[Abstract][Full Text]

243. Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Nov 23;377(21):2099.

244. Davies MJ, Drexel H, Jornayvaz FR, et al. Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovasc Diabetol. 2022 Aug 4;21(1):144.[Abstract][Full Text]

245. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program. Circulation. 2018 Jul 31;138(5):458-68.[Abstract][Full Text]

246. Furtado RHM, Bonaca MP, Raz I, et al. Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation. 2019 May 28;139(22):2516-27.[Abstract][Full Text]

247. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020 Oct 8;383(15):1425-35.[Abstract][Full Text]

248. Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020 Dec 8;142(23):2205-15.[Abstract][Full Text]

249. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021 Feb 1;6(2):148-58.[Abstract][Full Text]

250. Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in heart failure: a review of current evidence. Int J Heart Fail. 2023 Apr;5(2):82-90.[Abstract][Full Text]

251. Fan G, Guo DL. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: a meta-analysis of randomized controlled trials. Eur J Intern Med. 2023 Aug;114:49-57.[Abstract][Full Text]

252. Huang YL, Xu XZ, Liu J, et al. Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis. BMC Cardiovasc Disord. 2023 Jun 9;23(1):293.[Abstract][Full Text]

253. Zhang N, Wang Y, Tse G, et al. Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 Feb 3;28(17):1961-73.[Abstract][Full Text]

254. Wang Y, Zhong Y, Zhang Z, et al. Effect of sodium-glucose cotransporter protein-2 inhibitors on left ventricular hypertrophy in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Jan 9;13:1088820.[Abstract][Full Text]

255. Theofilis P, Antonopoulos AS, Katsimichas T, et al. The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis. Pharmacol Res. 2022 Jun;180:106243.[Abstract]

256. Aldafas R, Crabtree T, Alkharaiji M, et al. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024 Jan 2;53(1):afad254.[Abstract][Full Text]

257. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.[Full Text]

258. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022 May 10;145(19):1460-70.[Abstract][Full Text]

259. Mc Causland FR, Claggett BL, Vaduganathan M, et al. Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol. 2024 Feb 1;9(2):144-52.[Abstract][Full Text]

260. European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. Feb 2017 [internet publication].[Full Text]

261. US Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). August 2020 [internet publication][Full Text]

262. US Food and Drug Administration. FDA drug safety communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. August 2018 [internet publication].[Full Text]

263. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier's gangrene (necrotising fasciitis of the genitalia or perineum). Feb 2019 [internet publication].[Full Text]

264. Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019 Feb 28;18(1):20.[Abstract][Full Text]

265. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021 Jan 14;384(2):129-39.[Abstract][Full Text]

266. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021 Jan 14;384(2):117-28.[Abstract][Full Text]

267. Chen MB, Xu RJ, Zheng QH, et al. Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Aug 14;99(33):e20875.[Abstract][Full Text]

268. Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019 Jun;42(6):1147-54.[Abstract][Full Text]

269. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021 Sep 15;20(1):189.[Abstract][Full Text]

270. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-30.[Abstract]

271. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019 Aug 29;381(9):841-51.[Abstract][Full Text]

272. Guo X, Sang C, Tang R, et al. Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes. Diabetes Obes Metab. 2023 Apr;25 Suppl 1:53-63.[Abstract][Full Text]

273. Green JB, Everett BM, Ghosh A, et al. Cardiovascular outcomes in GRADE (glycemia reduction approaches in type 2 diabetes: a comparative effectiveness study). Circulation. 2024 Mar 26;149(13):993-1003.[Abstract]

274. Wang L, Xin Q, Wang Y, et al. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021 Sep;171:105765.[Abstract]

275. Rodriguez-Valadez JM, Tahsin M, Fleischmann KE, et al. Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression. Diabetes Care. 2023 Jun 1;46(6):1300-10.[Abstract][Full Text]

276. Banerjee M, Pal R, Mukhopadhyay S, et al. GLP-1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2023 Jun 16;108(7):1806-12.[Abstract][Full Text]

277. Li J, Ji C, Zhang W, et al. Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: a systematic review and Meta-analysis. J Diabetes Complications. 2023 Jan;37(1):108362.[Abstract]

278. Wei J, Yang B, Wang R, et al. Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: an eight RCTs meta-analysis. Front Endocrinol (Lausanne). 2022;13:1007980.[Abstract][Full Text]

279. Westerink J, Matthiessen KS, Nuhoho S, et al. Estimated life-years gained free of new or recurrent major cardiovascular events with the addition of semaglutide to standard of care in people with type 2 diabetes and high cardiovascular risk. Diabetes Care. 2022 May 1;45(5):1211-8.[Abstract][Full Text]

280. Merza N, Akram M, Mengal A, et al. The safety and efficacy of GLP-1 receptor agonists in heart failure patients: a systematic review and meta-analysis. Curr Probl Cardiol. 2023 May;48(5):101602.[Abstract]

281. Ferreira JP, Saraiva F, Sharma A, et al. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials. Diabetes Obes Metab. 2023 Jun;25(6):1495-502.[Abstract]

282. Liarakos AL, Tentolouris A, Kokkinos A, et al. Impact of glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: a narrative review. J Diabetes Complications. 2023 Feb;37(2):108390.[Abstract]

283. Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021 Jul 17;398(10296):262-76.[Abstract]

284. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med. 2014 Feb 27;370(9):794-7.[Full Text]

285. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010 Apr;151(4):1473-86.[Abstract][Full Text]

286. Hu W, Song R, Cheng R, et al. Use of GLP-1 Receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022 Jul 11;13:927859.[Abstract][Full Text]

287. Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023 Feb 1;46(2):384-90.[Abstract][Full Text]

288. Thompson CA, Stürmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care. 2023 Feb 1;46(2):249-51.[Full Text]

289. European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists​. Jul 2023 [internet publication].[Full Text]

290. Albert SG, Wood EM, Ahir V. Glucagon-like peptide 1-receptor agonists and A1c: good for the heart but less so for the eyes? Diabetes Metab Syndr. 2023 Jan;17(1):102696.[Abstract]

291. Qian W, Liu F, Yang Q. Effect of glucagon-like peptide-1 receptor agonists in subjects with type 2 diabetes mellitus: a meta-analysis. J Clin Pharm Ther. 2021 Dec;46(6):1650-8.[Abstract][Full Text]

292. Yoshida Y, Joshi P, Barri S, et al. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - a systematic review and meta-analysis. J Diabetes Complications. 2022 Aug;36(8):108255.[Abstract]

293. Lim CE, Pasternak B, Eliasson B, et al. Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol. 2023 Jun 1;30(8):634-43.[Abstract][Full Text]

294. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71.[Abstract][Full Text]

295. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12;298(10):1189-95.[Abstract]

296. Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010 Apr 27;121(16):1868-77.[Abstract][Full Text]

297. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med. 2007 Jul 5;357(1):28-38.[Abstract][Full Text]

298. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010 Jul 26;170(14):1191-201.[Abstract]

299. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007 Jul 5;357(1):67-9.[Abstract][Full Text]

300. European Medicines Agency. Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim).​ Sep 2010 [internet publication].[Full Text]

301. Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017 Jan 5;7(1):e013927.[Abstract][Full Text]

302. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007 Sep 12;298(10):1180-8.[Abstract]

303. Zhou Y, Huang Y, Ji X, et al. Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab. 2020 May 1;105(5):dgz252.[Abstract][Full Text]

304. Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Curr Diab Rep. 2019 Nov 27;19(12):151.[Abstract][Full Text]

305. U.S. Food and Drug Administration. FDA drug safety communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer.​ Dec 2017 [internet publication].[Full Text]

306. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, et al. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32(3):187-202.[Abstract]

307. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015 Jul 21;314(3):265-77.[Abstract][Full Text]

308. Filipova E, Uzunova K, Kalinov K, et al. Pioglitazone and the risk of bladder cancer: a meta-analysis. Diabetes Ther. 2017 Aug;8(4):705-26.[Abstract][Full Text]

309. Tang H, Shi W, Fu S, et al. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2018 Apr;7(4):1070-80.[Abstract][Full Text]

310. U.S Food and Drug Administration. Drugs@FDA: FDA-approved drugs: ACTOS (pioglitazone hydrochloride). Dec 2016 [internet publication].[Full Text]

311. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009 Mar 24;180(8):821-7.[Abstract][Full Text]

312. Sathya B, Davis R, Taveira T, et al. Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2013 Jun 6;102(1):8-15.[Abstract]

313. de Mulder M, Umans VA, Cornel JH, et al. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med. 2013 Nov 11;173(20):1896-904.[Abstract][Full Text]

314. Finfer S, Chittock DR, Su SY, et al; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.[Abstract][Full Text]

315. Inzucchi SE, Siegel MD. Glucose control in the ICU: how tight is too tight? N Engl J Med. 2009 Mar 26;360(13):1346-9.[Abstract]

316. Kirdemir P, Yildirim V, Kiris I, et al. Does continuous insulin therapy reduce postoperative supraventricular tachycardia incidence after coronary artery bypass operations in diabetic patients? J Cardiothorac Vasc Anesth. 2008 Jun;22(3):383-7.[Abstract]

317. Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004 Mar 30;109(12):1497-502.[Abstract][Full Text]

318. Wang YY, Hu SF, Ying HM, et al. Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis. BMC Endocr Disord. 2018 Jun 22;18(1):42.[Abstract][Full Text]

319. Shi S, Gouskova N, Najafzadeh M, et al. Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. BMJ Open. 2021 Sep 13;11(9):e050335.[Abstract][Full Text]

320. Brouwer TF, Vehmeijer JT, Kalkman DN, et al. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care. 2018 Jun;41(6):1142-8.[Abstract]

321. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015 May 23;385(9982):2047-56.[Abstract]

322. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28(7):601-31.[Abstract]

323. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-85.[Abstract][Full Text]

324. Liakos CI, Papadopoulos DP, Sanidas EA, et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs. 2021 Mar;21(2):123-37.[Abstract]

325. Carnovale C, Gringeri M, Battini V, et al. Beta-blocker-associated hypoglycaemia: new insights from a real-world pharmacovigilance study. Br J Clin Pharmacol. 2021 Aug;87(8):3320-31.[Abstract][Full Text]

326. Dimakos J, Cui Y, Platt RW, et al. Concomitant use of sulfonylureas and beta-blockers and the risk of severe hypoglycemia among patients with type 2 diabetes: a population-based cohort study. Diabetes Care. 2023 Feb 1;46(2):377-83.[Abstract][Full Text]

327. Farkouh ME, Godoy LC, Brooks MM, et al. Influence of LDL-cholesterol lowering on cardiovascular outcomes in patients with diabetes mellitus undergoing coronary revascularization. J Am Coll Cardiol. 2020 Nov 10;76(19):2197-207.[Abstract][Full Text]

328. Giugliano RP, Cannon CP, Blazing MA, et al; IMPROVE-IT Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 20;137(15):1571-82.[Abstract][Full Text]

329. Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023 Mar 14;44(11):972-83.[Abstract][Full Text]

330. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-107.[Abstract][Full Text]

331. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-22.[Abstract][Full Text]

332. Kulshreshtha M. An update on new cholesterol inhibitor: bempedoic acid. Curr Cardiol Rev. 2022;18(2):e141221198875.[Abstract][Full Text]

333. Dai L, Zuo Y, You Q, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2021 Jul 23;28(8):825-33.[Abstract][Full Text]

334. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023 Apr 13;388(15):1353-64.[Abstract]

335. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020 Apr 16;382(16):1507-19.[Abstract][Full Text]

336. ClinicalTrials.gov. A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). ClinicalTrials.gov Identifier: NCT03705234. ​Nov 2023 [internet publication].[Full Text]

337. Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. Eur Heart J. 2021 Dec 14;42(47):4807-17.[Abstract][Full Text]

338. Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020 Oct;22(suppl j):J34-J48.[Abstract][Full Text]

339. Ajjan RA, Kietsiriroje N, Badimon L, et al. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J. 2021 Jun 14;42(23):2235-59.[Abstract][Full Text]

340. Pistrosch F, Matschke JB, Schipp D, et al. Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. Diabetologia. 2021 Dec;64(12):2701-12.[Abstract][Full Text]

341. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016 Sep 6;134(10):e123-55.[Full Text]

342. Writing Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022 Jan 18;79(2):e21-129.[Abstract][Full Text]

343. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-467.[Full Text]

344. Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective - 2021 update. Circulation. 2021 Feb 9;143(6):583-96.[Abstract][Full Text]

345. Grines C, Patel A, Zijlstra F, et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003 Jan;145(1):47-57.[Abstract]

346. Marfella R, Sasso FC, Siniscalchi M, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab. 2012 Aug;97(8):2862-71.[Abstract]

347. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165.[Abstract][Full Text]

348. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2017 May 2;69(17):2212-41.[Abstract][Full Text]

349. Farkouh ME, Domanski M, Dangas GD, et al; FREEDOM Follow-On Study Investigators. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM follow-on study. J Am Coll Cardiol. 2019 Feb 19;73(6):629-38.[Abstract]

350. Wang R, Serruys PW, Gao C, et al. Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. Eur Heart J. 2021 Dec 28;43(1):56-67.[Abstract][Full Text]

351. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016 Dec 8;375(23):2223-35.[Abstract]

352. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010 Feb 2;55(5):432-40.[Abstract]

353. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013 Feb 23;381(9867):629-38.[Abstract]

354. Kappetein AP, Head SJ, Morice MC, et al; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013 May;43(5):1006-13.[Abstract][Full Text]

355. Farkouh ME, Domanski M, Sleeper LA, et al; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012 Dec 20;367(25):2375-84.[Abstract][Full Text]

356. Bypass Angioplasty Revascularization Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000 Apr;35(5):1122-9.[Abstract]

357. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007 Apr 2;49(15):1600-6.[Abstract][Full Text]

358. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005 Mar 23;293(12):1501-8.[Abstract][Full Text]

359. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol. 2007 Feb 13;49(6):643-56.[Abstract]

360. Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010 Mar 16;55(11):1067-75.[Abstract]

361. Maresta A, Varani E, Balducci M, et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol. 2008 Jun 1;101(11):1560-6.[Abstract]

362. Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol. 2008 Jun 24;51(25):2385-95.[Abstract]

363. Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008 Nov 25;118(22):2277-85.[Abstract]

364. Frye RL, August P, Brooks MM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11;360(24):2503-15.[Abstract][Full Text]

365. De Luca G, Dirksen MT, Spaulding C, et al; DESERT Cooperation. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013 May 1;111(9):1295-304.[Abstract]

366. Newman JD, Anthopolos R, Mancini GBJ, et al. Outcomes of participants with diabetes in the ISCHEMIA trials. Circulation. 2021 Oct 26;144(17):1380-95.[Abstract][Full Text]

367. Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23;130(25):e344-426.[Full Text]

368. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16.[Abstract][Full Text]

369. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020 Apr 9;382(15):1395-407.[Abstract][Full Text]

370. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006 Nov 2;355(18):1903-11.

371. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006 Feb 2;354(5):449-61.[Abstract][Full Text]

372. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic Kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-29.[Abstract][Full Text]

373. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-63.[Abstract][Full Text]

374. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-84.[Abstract][Full Text]

375. Bansal S, Canziani MEF, Birne R, et al. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19;14(3):e076444.[Abstract][Full Text]

376. Agarwal R, Pitt B, Rossing P, et al. Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone. JAMA Cardiol. 2023 Aug 1;8(8):732-41.[Abstract][Full Text]

377. Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation. 2024 Feb 6;149(6):450-62.[Abstract][Full Text]

378. Yoon KH, Kang J, Kwon SC, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab. 2020 Aug;22(8):1292-301.[Abstract][Full Text]

379. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021 Sep 2;385(10):896-907.[Abstract][Full Text]

380. Gerstein HC, Li Z, Ramasundarahettige C, et al. Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O trial. Circulation. 2023 Mar 28;147(13):1004-13.[Abstract][Full Text]

381. Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022 Feb 22;145(8):565-74.[Abstract][Full Text]

382. Pratley RE, Jacob S, Baek S, et al. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care. 2022 Jan;10(1):e002207.[Abstract][Full Text]

383. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022 Nov 26;400(10366):1869-81.[Abstract]

384. Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023 Aug 12;402(10401):529-44.[Abstract]

385. ClinicalTrials.gov. A study of retatrutide (LY3437943) in participants with type 2 diabetes mellitus who have obesity or overweight (TRIUMPH-2).​ ClinicalTrials.gov Identifier: NCT05929079. Aug 2024 [internet publication].[Full Text]

386. Frias JP, Hsia S, Eyde S, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet. 2023 Aug 5;402(10400):472-83.[Abstract]

387. ClinicalTrials.gov. A study of orforglipron in adult participants with obesity or overweight and type 2 diabetes (ATTAIN-2).​ ClinicalTrials.gov Identifier: NCT05872620. Jun 2024 [internet publication].​[Full Text]

388. ClinicalTrials.gov. A study of daily oral orforglipron (LY3502970) compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk (ACHIEVE-4).​ ClinicalTrials.gov Identifier: NCT05803421. Aug 2024 [internet publication].​[Full Text]

389. ClinicalTrials.gov. A long-term safety study of orforglipron (LY3502970) in participants with type 2 diabetes (ACHIEVE-J).​ ClinicalTrials.gov Identifier: NCT06010004. Aug 2024 [internet publication].​[Full Text]

390. ClinicalTrials.gov. A study of orforglipron (LY3502970) in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone (ACHIEVE-1).​ ClinicalTrials.gov Identifier: NCT05971940. Aug 2024 [internet publication].​[Full Text]

391. ClinicalTrials.gov. A study of orforglipron (LY3502970) compared with semaglutide in participants with type 2 diabetes inadequately controlled with metformin (ACHIEVE-3). ClinicalTrials.gov Identifier: NCT06045221. Aug 2024 [internet publication].[Full Text]

392. Yao H, Zhang A, Li D, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024 Jan 29;384:e076410.[Abstract][Full Text]

393. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023 Aug 26;402(10403):720-30.[Abstract]

394. Roubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). Diabetes Care. 2024 Mar 1;47(3):467-70.[Abstract]

395. Montreal Heart Institute. Clinical study COLCOT-T2D: prevention of heart disease in people with type 2 diabetes​. 2022 [internet publication].[Full Text]

396. Jiang H, Pang S, Zhang Y, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in chinese patients with type 2 diabetes. Nat Commun. 2022 Jun 24;13(1):3613.[Abstract][Full Text]

397. ​Benson C, Tham LS, Du YU, et al. 333-OR: oxyntomodulin analog LY3305677 (LY) improves glycemic control and weight loss in healthy volunteers and subjects with type 2 diabetes (T2D). Diabetes. 2022 Jun 1;71(1 suppl):333.[Full Text]

398. Zhang B, Cheng Z, Chen J, et al. Efficacy and safety of mazdutide in chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care. 2024 Jan 1;47(1):160-8.[Abstract][Full Text]

399. ClinicalTrials.gov. Safety and efficacy of bexagliflozin as monotherapy in patients with type 2 diabetes.​ ClinicalTrials.gov Identifier: NCT02715258. Jun 2021 [internet publication].​[Full Text]

400. ​ClinicalTrials.gov. Safety and efficacy of bexagliflozin compared to placebo as add-on therapy to metformin in type 2 diabetes subjects.​ ClinicalTrials.gov Identifier: NCT03259789. Jul 2021 [internet publication].[Full Text]

401. ClinicalTrials.gov. Safety and efficacy of bexagliflozin compared to glimepiride as add-on therapy to metformin in type 2 diabetes subjects.​ ClinicalTrials.gov Identifier: NCT02769481. May 2021 [internet publication].​[Full Text]

402. ClinicalTrials.gov. Safety and efficacy of bexagliflozin compared to sitagliptin as add-on therapy to metformin in type 2 diabetes subjects.​ ClinicalTrials.gov Identifier: NCT03115112. Jun 2021 [internet publication].​[Full Text]

403. ​ClinicalTrials.gov. Safety and efficacy of bexagliflozin in type 2 diabetes mellitus patients with moderate renal impairment.​ ClinicalTrials.gov Identifier: NCT02836873. Jun 2021 [internet publication].[Full Text]

404. ClinicalTrials.gov. Bexagliflozin efficacy and safety trial (BEST).​ ClinicalTrials.gov Identifier: NCT02558296. Jul 2021 [internet publication].​[Full Text]

405. Allegretti AS, Zhang W, Zhou W, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019 Sep;74(3):328-37.[Abstract][Full Text]

406. Halvorsen YD, Conery AL, Lock JP, et al. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2023 Oct;25(10):2954-62.[Abstract][Full Text]

407. Xie L, Han J, Cheng Z, et al. Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: a 24-week, randomized, double-blind, active-controlled, phase 3 trial. J Diabetes. 2024 Apr;16(4):e13526.[Abstract][Full Text]

408. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 2023 Aug 29;148(9):e9-119.[Abstract][Full Text]

409. Diabetes Canada (Canadian Diabetes Association). Clinical practice guidelines for the prevention and management of diabetes in Canada. 2018 [internet publication].[Full Text]

410. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: preventive medication. August 2022 [internet publication].[Full Text]

411. Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association. Diabetes Care. 2020 Jul;43(7):1636-49.[Full Text]

412. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2020 Dec 1;105(12):dgaa674.[Abstract][Full Text]

413. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017 Apr;23(Suppl 2):1-87.[Abstract][Full Text]

414. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Sep;97(9):2969-89.[Abstract][Full Text]

415. World Gastroenterology Organisation; International Federation for the Surgery of Obesity and Metabolic Diseases​. Guideline on obesity. 2023 [internet publication].[Full Text]

416. Kerola AM, Juonala M, Palomäki A, et al. Case fatality of patients with type 1 diabetes after myocardial infarction. Diabetes Care. 2022 Jul 7;45(7):1657-65.[Abstract][Full Text]

417. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019 Aug 13;140(7):e294-324.[Abstract][Full Text]

418. MacDonald MR, Petrie MC, Varvani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Jun;29(11):1377-85.[Abstract][Full Text]

419. Varkevisser RDM, Birnie E, Vollenbrock CE, et al. Cardiovascular risk management in people with type 1 diabetes: performance using three guidelines. BMJ Open Diabetes Res Care. 2022 Jul;10(4):e002765.[Abstract][Full Text]

420. Martín Enguix D, Hidalgo Rodríguez A, Sánchez Cambronero M, et al. Application of the individualized objectives defined by the European 2019 lipid guidelines in patients with type 2 diabetes. Clin Investig Arterioscler. 2022 Jan-Feb;34(1):19-26.[Abstract]

421. Bullock JE. Provider adherence to American Diabetes Association cardiovascular risk-reduction guidelines: an integrative review. J Am Assoc Nurse Pract. 2024 Jan 1;36(1):17-22.[Abstract]

422. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023 Feb 21;147(8):e93-621.[Abstract][Full Text]

423. Kamalesh M. Heart failure in diabetes and related conditions. J Card Fail. 2007 Dec;13(10):861-73.[Abstract]

424. Bruce DG, Davis WA, Casey GP, et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia. 2008 Feb;51(2):241-8.[Abstract]

425. Mark PB, Carrero JJ, Matsushita K, et al. Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study. Eur Heart J. 2023 Apr 1;44(13):1157-66.[Abstract][Full Text]

426. Bakhit M, Fien S, Abukmail E, et al. Cardiovascular disease risk communication and prevention: a meta-analysis. Eur Heart J. 2024 Mar 27;45(12):998-1013.[Abstract][Full Text]

427. Pagidipati NJ, Navar AM, Pieper KS, et al. Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: international insights from the TECOS trial (trial evaluating cardiovascular outcomes with sitagliptin). Circulation. 2017 Sep 26;136(13):1193-203.[Abstract]

428. Wing RR, Bolin P, Brancati FL, et al; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11;369(2):145-54.[Abstract][Full Text]

429. Rangaswami J, Bhalla V, de Boer IH, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020 Oct 27;142(17):e265-86.[Abstract][Full Text]

430. Marx N, Husain M, Lehrke M, et al. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022 Dec 13;146(24):1882-94.[Abstract][Full Text]

431. Eliasson B, Ekelund J, Holmberg CN, et al. Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register. Eur J Prev Cardiol. 2023 May 9;30(7):546-51.[Abstract][Full Text]